Pieris Pharmaceuticals has announced the initiation of a Phase 1 study of PRS-220, an anticalin inhalation solution that targets connective tissue growth factor (CTGF), which the company is developing for the treatment of fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). In June 2021, Pieris announced that it would develop PRS-220 for IPF and for pulmonary fibrosis following COVID infection.
In 2017, AstraZeneca acquired rights to Pieris inhaled anticalin therapies, including PRS-060, a dry powder IL-4 receptor alpha inhibitor for the treatment of asthma, and Pieris and AZ are currently co-developing PRS-060/AZD1402 for the treatment of moderate-to-severe asthma.
Pieris President and CEO Stephen S. Yoder commented, “The initiation of this trial is an important step in the development of PRS-220, a fully proprietary program that we believe has the potential to offer a meaningful improvement in the quality of life for patients suffering from this rare and, ultimately, terminal disease. PRS-220 is the second inhaled respiratory program we have brought into the clinic, and we look forward to reporting the results from this study next year.”
Read the Pieris Pharmaceuticals press release.
